Results 291 to 300 of about 147,983 (340)

DIGitoxin to Improve ouTcomes in patients with advanced chronic Heart Failure (DIGIT‐HF): Baseline characteristics compared to recent randomized controlled heart failure trials

European Journal of Heart Failure, EarlyView.
Effects of digitoxin compared to placebo on efficacy and safety in patients with heart failure and reduced ejection fraction (HFrEF). Primary endpoint: time to all‐cause death and first hospitalization for worsening heart failure (whatever occurs first). ACEi, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin
Udo Bavendiek, Nele Henrike Thomas, Dominik Berliner, Xiaofei Liu, Johannes Schwab, Andreas Rieth, Lars S. Maier, Sven Schallhorn, Eleonora Angelini, Samira Soltani, Fabian Rathje, Mircea‐Andrei Sandu, Welf Geller, Thomas Gaspar, Rainer Hambrecht, Marija Zdravkovic, Sebastian Philipp, Dragana Kosevic, Georg Nickenig, Daniel Scheiber, Sebastian Winkler, Peter Moritz Becher, Philipp Lurz, Martin Hülsmann, Maria von Karpowitz, Christoph Schröder, Barbara Neuhaus, Anika Seltmann, Heiko von der Leyen, Christian Veltmann, Stefan Störk, Michael Böhm, Armin Koch, Anika Großhennig, Johann Bauersachs, on behalf of the DIGIT‐HF Study Group   +35 more
wiley   +1 more source

Intravenous ferric carboxymaltose in heart failure with iron deficiency (FAIR‐HF2 DZHK05 trial): Sex‐specific outcomes

European Journal of Heart Failure, EarlyView.
Abstract Aims Intravenous iron has emerged as a guideline‐recommended therapy in patients with heart failure and iron deficiency, but the potential sex‐related differences in efficacy are unknown. We aimed to assess sex‐specific outcomes in the Intravenous Iron in Patients with Systolic Heart Failure and Iron Deficiency to Improve Morbidity & Mortality
Mahir Karakas, Tim Friede, Javed Butler, Khawaja M. Talha, Marius Placzek, Thomas Asendorf, Monika Diek, Anna Nosko, Adriane Stas, Stefan Kluge, Dominik Jarczak, Geraldine DeHeer, Meike Rybczynski, Antoni Bayes‐Genis, Michael Böhm, Andrew J.S. Coats, Frank Edelmann, Gerasimos Filippatos, Gerd Hasenfuß, Wilhelm Haverkamp, Mitja Lainscak, Ulf Landmesser, Iain C. Macdougall, Bela Merkely, Burkert M. Pieske, Fausto J Pinto, Tienush Rassaf, Jennifer K. Visser‐Rogers, Giuseppe Rosano, Maurizio Volterrani, Stephan von Haehling, Markus S. Anker, Wolfram Doehner, Hüseyin Ince, Friedrich Koehler, Gianluigi Savarese, Muhammad Shahzeb Khan, Ursula Rauch Kröhnert, Tommaso Gori, Teresa Trenkwalder, Ibrahim Akin, Christina Paitazoglou, Iwona Kobielusz‐Gembala, Luca Kuthi, Norbert Frey, Manuela Licka, Stefan Kääb, Karl‐Ludwig Laugwitz, Piotr Ponikowski, Stefan D. Anker   +49 more
wiley   +1 more source

Cardio‐microcurrent device treatment for heart failure with reduced ejection fraction: Results from the C‐MIC II open‐label randomized controlled trial

European Journal of Heart Failure, EarlyView.
Efficacy and Safety of C‐MIC Device in Patients with Heart Failure with Reduced Ejection Fraction. 6MWD, 6‐min walk distance; CI, confidence interval; KCCQ‐OSS, Kansas City Cardiomyopathy Questionnaire overall summary score; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.
Jesus E. Rame, Jan D. Schmitto, Dragana N. Kosevic, Tamara Kovacevic‐Preradovic, Sasko Jovev, Marija Zdravkovic, Nermir Granov, Tanja Popov, Igor Rudez, Petar Vukovic, Velibor Ristic, Petr Neuzil, Annette Holtdirk, Arjang Ruhparwar, Muhammad Shahzeb Khan, Hans‐Dirk Düngen, Kersten Brandes, Peter Goettel, Johannes Mueller, Faouzi Kallel, Tim Friede, Miodrag Peric, Marat Fudim, Stefan D. Anker, for the C‐MIC II Trial Investigators   +24 more
wiley   +1 more source

Gut microbiome alterations precede graft rejection in kidney transplantation patients

Holle J, Reitmeir R, Behrens F, Singh D, Schindler D, Potapenko O, McParland V, Anandakumar H, Kanzelmeyer N, Sommerer C, Hartleif S, Andassy J, Heemann U, Neuenhahn M, Forslund-Startceva SK, Gerhard M, Oh J, Wilck N, Löber U, Bartolomaeus H, members of the German Center of Infection Research Transplant Cohort.   +20 more
europepmc   +1 more source

Correction: Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT. [PDF]

Bone Marrow Transplant
Sureda A, Carpenter PA, Bacigalupo A, Bhatt VR, de la Fuente J, Ho A, Kean L, Lee JW, Sánchez-Ortega I, Savani BN, Schetelig J, Stadtmauer EA, Takahashi Y, Atsuta Y, Koreth J, Kröger N, Ljungman P, Okamoto S, Popat U, Soiffer R, Stefanski HE, Kharfan-Dabaja MA.   +21 more
europepmc   +1 more source

Smart and Sustainable Regeneration of Fouled Desalination Membranes Using Artificial Intelligence

Global Challenges, EarlyView.
Artificial intelligence (AI) is transforming membrane regeneration by addressing challenges like fouling, aging, and scalability. This study compares conventional and AI‐driven approaches, highlighting advancements through models like CNN, RNN, and IoT integration.
Muhammad Mubashir, Mustakeem Mustakeem, Ammar Alnumani, Abdulrahman Abutaleb, Ali Hamoud Naji Sumayli, Tausif Ahmad, Muhammad Rizwan Azhar   +6 more
wiley   +1 more source

Heart failure in two male patients with late‐onset Fabry mutation (IVS4 + 919G > A)

ESC Heart Failure, Volume 12, Issue 2, Page 1508-1513, April 2025.
Xufei Yang, Chunlan Deng, Xiaogang Guo, Hui Yan   +3 more
wiley   +1 more source

Somatic cell reprogramming for Parkinson's disease treatment

Ibrain, Volume 11, Issue 1, Page 59-73, Spring 2025.
The fundamental purpose of cell reprogramming to treat Parkinson's disease is to generate dopaminergic neurons (DAN) and do transplantation. There are two ways to accomplish this. One method is to induce cells into induced DA neurons (iDAN) directly or to induce cells into induced pluripotent stem cells and ultimately into iDAN in vitro. Another option
Xiaozhuo Li, Kevin Fang, Fengping Wang
wiley   +1 more source

Sizing and concentration analysis of cfDNA using Biabooster technology: Results from a prospective plasma‐based collection of 77 patients with locally advanced unresectable esophageal cancer

International Journal of Cancer, EarlyView.
What's New? This study introduces a novel approach for detecting locally advanced esophageal carcinoma using cell‐free DNA (cfDNA) analysis through a highly sensitive fragmentome assay. Unlike traditional sequencing‐based methods that are limited by the absence of specific mutations in esophageal tumors, our method offers an alternative by quantifying ...
Anouchka Modesto, Sophie Gibert, Caroline Delmas, David Tougeron, Amaury Paumier, Alexandre Taillez, Samuel Le Sourd, Delphine Argo Leignel, Philippe Ronchin, Ariane Darut Jouve, Véronique Vendrely, Olivier Riou, Jérôme Martin‐Babau, Thomas Leroy, Laurent Quéro, Naïma Hanoun, Pierre Cordelier, Veronica Pezzella, Jean Pierre Delord, Rosine Guimbaud, Elizabeth Moyal, Catherine Seva   +21 more
wiley   +1 more source

Renal transplantation in the highly sensitized patient: The role of thoracic duct drainage, plasmapheresis, and staph A immunodepletion [PDF]

, 1990
Shapiro, R, Starzl, TE
core